Opendata, web and dolomites

PulseHaler

PulseHaler: Improving the Lives of COPD Patients

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PulseHaler project word cloud

Explore the words cloud of the PulseHaler project. It provides you a very rough idea of what is the project "PulseHaler" about.

terminal    pulsehaler    alveolar    venice    world    annually    airways    air    standard    al    tests    die    small    10    dyspnoea    invasive    respiratory    successfully    cigarette    treat    amount    stomach    minute    city    lung    fold    collapse    fuels    chronic    drug    goes    smoking    bronchitis    inhaled    countries    group    airway    markedly    cough    debilitating    obstructive    unprecedented    equivalent    drugs    6mw    core    efficacy    cooking    biomass    source    pathophysiology    kills    mouth    exposure    pollutants    limitations    approximately    bronchioles    people    improvements    spirometry    emphysema    massive    million    pulmonary    capacity    functions    respinova    enhancement    copd    patients    named       time    medical    zone    airflow    size    et    device    effect    trade    walk    first    halbert    breathing    dramatically    difficulty    entire    index    validated    efficiency    feeling    safety    demonstrated    270    history    adults    penetration    pollution    reduce    pharmaceutical    progressive    care    functional    ed    disease    2003    clinical   

Project "PulseHaler" data sheet

The following table provides information about the project.

Coordinator
RESPINOVA LTD 

Organization address
address: 8 HACHOSHLIM ST.
city: HERZLIYA PITUACH
postcode: 4672408
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website http://www.respinova.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.4. (Active ageing and self-management of health)
2. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.3.1.6. (Health care provision and integrated care)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-12-01   to  2018-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    RESPINOVA LTD IL (HERZLIYA PITUACH) coordinator 50˙000.00

Map

 Project objective

Chronic obstructive pulmonary disease (COPD) is a group of progressive, debilitating respiratory conditions, including emphysema and chronic bronchitis, characterized by difficulty breathing, lung airflow limitations, cough, and markedly reduced functional capacity. COPD often is associated with a history of cigarette smoking or exposure to pollutants. It kills approximately 270,000 people in the EU annually, equivalent to the size of the entire city of Venice. It affects 4% and 10% of adults in Europe (Halbert et al., 2003). World-wide 5-10% are affected and 3 million die each year (source: WHO). In the developing countries, COPD has been growing dramatically due to increased air pollution, smoking and massive use of biomass fuels for cooking. Respinova has developed a novel non-invasive technology and medical device named the PulseHaler™, that aims to treat the core of the COPD pathophysiology – small airway collapse. The technology was successfully validated in two clinical studies. In the first study, PulseHaler was evaluated for its ability to open small airways. Clinical results demonstrated unprecedented improvements in the 6 minute walk test (6MW), spirometry lung functions tests and in the feeling of dyspnoea. All of these effects were above and beyond the effect of standard pharmaceutical care. In the second study, PulseHaler™ was successfully used as a new means for improved delivery of inhaled drugs to the terminal bronchioles and the alveolar zone in COPD patients. It resulted in three-fold enhancement of penetration index, a measure of efficiency of drug delivery. By improving the drug delivery, PulseHaler technology can enhance efficacy & safety of drug delivery. It can reduce the amount of drug required, ensure less drug goes to non-lung areas (mouth, stomach etc.), and reduce time required to deliver the drugs.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PULSEHALER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PULSEHALER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.4.;H2020-EU.2.1.1.;H2020-EU.2.3.1.;H2020-EU.3.1.6.)

CLINICOVERY (2018)

CLINICOVERY, a versatile, high quality, environmental-friendly, easy to use e-Clinical solution for clinical research

Read More  

ImmuneHunter (2017)

Bioinformatics platform for profiling of health: allowing early and accurate detection of multiple diseases simultaneously

Read More  

SensUS (2018)

SensUS: A non-invasive and quantitative ultrasound (QUS) device for an objective monitoring of the childbirth labour process.

Read More